Year-End Report 2015 Fourth Quarter Net sales increased

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 27, 2016 at 2:15 AM

Year-End Report 2015

Fourth Quarter · Net sales increased by 2%, amounting to SEK 1,685.5 (1,649.7) million · EBITDA excluding divested operations during 2014 and non-recurring items totalled SEK 7.0 (15.2) million · Operating profit excluding divested operations during 2014 and non-recurring items amounted to SEK -5.7 (8.0) million · Including divested operations during 2014 and non-recurring items operating profit amounted to SEK -31.9 (-3.6) million · Net income amounted to SEK -29.4 (-7.0) million · Basic earnings per share amounted to SEK -0.20 (-0.06) · Cash flow from operations, excluding changes in Qliro Financial Services’ lending to the public, amounted to SEK 142.8 (256.4) million · Operating profit is affected by non-recurring items of SEK 26.2 million related to Lekmer Full year 2015 · Net sales increased by 4%, coming in at SEK 5,174.1 (4,966.7) million. Including divested operations, net sales increased by 3% · EBITDA excluding divested operations during 2014 and non-recurring items totalled SEK -23.6 (34.8) million · Operating profit excluding operations divested in 2014 and non-recurring items amounted to SEK -65.6 (8.6) million · Operating profit including operations divested in 2014 and non-recurring items and amounted to SEK -122.7 (33.0) million · Net income amounted to SEK -101.6 (5.4) million · Basic earnings per share amounted to SEK -0.68 (0.02) · Cash flow from operations, excluding changes in Qliro Financial Services’ lending to the public, amounted to SEK -73.4 (74.7) million Comments by the CEO Paul Fischbein, President and CEO comments: “The fourth quarter held many positives but was also challenging. The Groups largest segment, CDON Marketplace, delivered both strong sales and a significant earnings improvement. During the year, we have implemented many important changes within CDON which now are starting to bear fruit. CDON is undergoing major changes and the result in the fourth quarter is a confirmation that we are heading in the right direction even if key measures remains, including a larger reorganization which we are working on now. Our newly established subsidiary Qliro Financial Services continued to develop in line with our high expectations. The large order volumes in the Group during the quarter also contributed to large business volumes for the Qliro payment solution and, one year after the launch, Qliro Financial Services reported positive earnings in the fourth quarter. Loans to the public amounted to approximately SEK 530 million at the end of the year, financed by around SEK 200 million by own funding. It has of course been pleasing to follow the development of Qliro Financial Services during the first year of operations and this result also gives an indication of the future potential in the segment. Next important steps include, among other things, the continued roll out of Qliro Financial Services, not least through a launch in Norway and the introduction of additional financial services after the expected approval to become a credit market company has been received from Finansinspektionen (the Swedish Financial Supervisory Authority). On the negative side we find Lekmer, where operational disturbances at the warehouse once again had a large impact on the company’s and the Group´s sales and earnings. The warehouse move and the deployment of the new warehouse system has been more complex than expected, which resulted in major operational consequences when volumes gradually increased during the quarter. At the end of November, the company decided to minimize its marketing and other sales promotion activities and to focus solely on delivering the orders which had already been made. As a result of the disturbances, Lekmer has in conjunction with the year-end closing expensed SEK 26 million related to inventory valuation which is presented under non-recurring items in the fourth quarter. 2015 was a turbulent year for Lekmer and the challenges in 2015 are fully related to Lekmer’s new warehouse. However, we estimate that the major operational problems are now behind us, even though it is expected to take another one to two quarters before Lekmer is back to the same good standing it was a year ago. We believe that Lekmer´s future high potential remains. Overall, the fourth quarter was a challenging quarter affected by external factors such as weather and currency effects at the same time as Lekmer’s warehouse experienced large operational disturbances. However, we see that our companies have strong market positions and, during 2015, the amount of active customers continued to increase and now amount to a bit over 4 million consumers in the Nordics. This creates very good conditions for an exciting future.” For additional information, please visit www.qlirogroup.com or contact: Paul Fischbein, President and Chief Executive Officer Tel: +46 (0) 10 703 20 00 Nicolas Adlercreutz, CFO Tel: +46 (0) 70 587 44 88 Questions from media, investors and research analysts: Erik Löfgren, Head of Communications Tel: +46 (0) 700 80 75 06 Email: press@qlirogroup.com, ir@qlirogroup.com About Qliro Group Qliro Group is a leading e-commerce group in the Nordic region. Established in 1999, the Group has expanded its product portfolio and is now a leading e -commerce player within consumer goods and lifestyle products through CDON.com, Lekmer, Nelly (Nelly.com, NLYman.com, Members.com), Gymgrossisten (Gymgrossisten.com/Gymsector.com, Bodystore.com, Milebreaker.com) and Tretti. The payment service solution Qliro is also part of the Group. In 2015, the Group generated revenue of SEK 5.2 billion. Qliro Group’s shares are listed on the Nasdaq Stockholm MidCap list under the ticker symbol “QLRO”. The information in this Year-End report is that which Qliro Group AB is required to disclose under the Securities Markets Act. This information was released for publication at 08:00 CET on 27 January 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Manhattan Associates Faces Investigation by KSF Law Firm

KSF Digs Into Manhattan Associates' Claims In the swirl of the financial world, you rarely see an investigation that doesn’t raise a few eyebrows. This time, it's Manhattan Associates, Inc. (NasdaqGS: MANH) squarely in the crosshairs of Kahn Swick & Foti, LLC (KSF), a pivotal player in securities litigation. You’ve got to wonder what dirt might be uncovered here,...

Breakthrough T1D Pushes Global T1D Awareness Forward

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Greenberg Traurig's Brad Kaufman: A Mentor of Resolute Impact

A Milestone for Mentorship at Greenberg Traurig In the often cutthroat jungle of law, finding someone who actually gives a damn about you is as rare as finding a unicorn. Yet, there it is—Brad Kaufman, at the helm of Greenberg Traurig's professional development, proving that mentorship can be more than just a checkbox on a quarterly review. Award for Exceptional...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

IEHP's Wellness Center Launch Faces Delay in California

Unexpected Delay for IEHP's Community Hub Straight outta Rancho Cucamonga, we've got some news that'll have folks in San Bernardino holding their breath a little longer. The Inland Empire Health Plan (or IEHP if you're part of the 1.4 million served by them) had folks pumped for their new Community Wellness Center. But guess what? They had to slam the brakes on the grand...

SmallRig Boosts Art-Driven Innovation in AI Era

The Interplay of Art and AI In a world where the lines between man and machine blur faster than ever, creators like SmallRig are boldly asking: what role should authenticity play when AI takes the stage? The Shenzhen International Art Museum and SmallRig stood shoulder to shoulder, tackling this head-scrambling question with a global gathering of art and tech giants. It's...

Beko Pushes for Policy Synergy Amidst Carbon Shakeup

When big names like Beko step up on the global stage, you pay attention. During the COP31 panels in Antalya, Türkiye, the company's brass made one thing clear: we need harmony in how climate, trade, and finance policies come together. The stakes? The very strength of industrial competitiveness as new carbon rules turn the heat up on manufacturing practices. The Call for...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...